POTENCY OF ORAL UN-DENATURED TYPE II COLLAGENIN THE TREATMENT OF OSTEOARTHRITIS, WITH SPECIFICAL RELATIONSHIP TO KNEE JOINT- A META-ANALYTIC REVIEW

2021 ◽  
pp. 6-10
Author(s):  
R K Guhan ◽  
Saran Karthik.S ◽  
Ashwin V Y ◽  
Venkatachalam. K ◽  
Yokesh M ◽  
...  

Introduction: One of the chronic progressive diseases of the elderly is Osteoarthritis. There is a wide spectrum of Nutraceuticals, for Osteoarthritis, but there does not exist, a convincing literature based evidence, in support of their denitive and specic rationale of utility. We here in, aim to evaluate the evidence in literature hither to available, for establishing the potency and efcaciousness of the indigenous type II collagen variant. Methods: st st A schematic search was performed of Pub Med, Scopus and the Google Scholar, from dates (1 December 2009 to 1 December 2020), with the search terms: 'Osteoarthritis', 'Nutraceuticals', 'Oral Collagen', 'Glucosamine', 'Chondroitin Sulfate', 'Acetaminophen' and 'Native Collagen'. Articles containing the following were included in the study: Randomized Control Trial and Clinical Trial, Primary data, OA and Oral Collagen studies related to joint disease. Total number of patients studied, the number of patients who were treated by Native Collagen Type II variant, Denatured Collagen Type II variant, Glucosamine, Chondroitin Sulfate and Acetaminophen.A number of studies using various scoring systems were incorporated in our study. Finally, all the functional outcomes, according to the VAS and WOMAC scores, were cumulatively tabulated, and analyzed schematically and their results deduced. Results: Multiple researches have been executed, to elucidate upon the efcacy and the safety, of Oral Collagen of the type II variant, in the medicaments prescribed for OA, especially relating to the Knee joint. Oral Collagen is administered, either in a Denatured or an Undenatured form .The results indicate , that out of all the Nutraceuticals, Undenatured/Native collagen of the type II variant, proved to be by far the most safe and signicantly more efcacious, compared to other Nutraceuticals. Although all the suggested treatments reduced the WOMAC and the VAS scores, here in UC II, showed more efciency and sustenance of the pain reduction, in both the assessment scores, in comparison with other orally administrated Nutraceuticals. Conclusion: Our Meta-Analysis concludes that, Type II Undenatured Collagen, is a relatively safe and also signicantly more efcient, in improving the joint function, ROM and for the alleviation of bone joint pain, in OA knee (Genu OA) patients.

2010 ◽  
Vol 37 (3) ◽  
pp. 656-664 ◽  
Author(s):  
STEEVE KWAN TAT ◽  
JEAN-PIERRE PELLETIER ◽  
FRANÇOIS MINEAU ◽  
NICOLAS DUVAL ◽  
JOHANNE MARTEL-PELLETIER

Objective.During osteoarthritis (OA), the altered metabolism of cartilage involves proinflammatory factors and matrix metalloprotease (MMP) activity. Studies showed that chondroitin sulfate (CS) may exert a positive effect on the cartilage. Because of differences in CS in terms of purity and the production/purification process, we compared the effects of 3 different types of CS on human OA cartilage.Methods.Three types of CS were tested: CS1 (porcine, purity 90.4%), CS2 (bovine, purity 96.2%), and CS3 (bovine, purity 99.9%). Treatment with CS at 200 and 1000 μg/ml was performed on human OA cartilage explants in the presence/absence of interleukin 1ß (IL-1ß), and the protein modulations of factors including prostaglandin E2 (PGE2), IL-6, and MMP-1 measured by ELISA. The CS effect on the expression of collagen type II was also investigated on OA chondrocytes using quantitative polymerase chain reaction.Results.In the presence of IL-1ß, CS2 at 1000 μg/ml significantly inhibited IL-6 and PGE2 production, and CS3 at 200 μg/ml markedly reduced the level of IL-6. CS1 was much less efficient at reducing the catabolic markers and in the absence of IL-1ß, it significantly increased IL-6 and MMP-1. IL-1ß significantly inhibited the gene expression level of collagen type II; only CS3 was able to limit this inhibition. CS1, in the presence or absence of IL-1ß, further markedly decreased collagen type II expression.Conclusion.Our data indicate that among the 3 tested CS, CS1 increased production of some catabolic pathways and inhibited the gene expression level of collagen type II. Our study provides new information in the context of prescribing CS for alleviating OA symptoms, as the purity and/or production/purification of the CS compound could orient the current OA disease process toward increased catabolic pathways.


Marine Drugs ◽  
2019 ◽  
Vol 17 (4) ◽  
pp. 223 ◽  
Author(s):  
Cumming ◽  
Hall ◽  
Hofman

The composition and properties of collagen in teleost (bony fish) cartilage have never been studied. In this study, we aimed to identify and characterise all collagen species in the nasal cartilage of hoki (Macruronus novaezelandiae). Four native collagen species were extracted using two techniques, and isolated with differential salt precipitation. We were able to assign the identity of three of these collagen species on the basis of solubility, SDS-PAGE and amino acid analyses. We found that hoki cartilage contains the major collagen, type II, and the minor collagens, type IX and type XI, which are homologous to those found in mammal and chicken cartilage. Using these extraction protocols, we also isolated a full-length type IX collagen from cartilage for the first time. In addition, we detected a 90 kDa, highly glycosylated collagen that has not been identified in any other species. For each isolate, structural and biochemical characterisations were performed using circular dichroism and Fourier transform infrared spectroscopy analyses, and the thermal denaturation properties were determined. Our results showed that the properties of hoki cartilage-derived collagens are similar to those of collagens in mammalian cartilage, indicating that teleost cartilage could provide biological ingredients for the development of biomaterials to treat cartilage-related illnesses.


2020 ◽  
Vol 2020 ◽  
pp. 1-11 ◽  
Author(s):  
Seul Ah. Lee ◽  
Bo-Ram Park ◽  
Sung-Min Moon ◽  
Joon Ho Hong ◽  
Do Kyung Kim ◽  
...  

Osteoarthritis (OA) is a degenerative joint disease characterized by cartilage degradation and inflammation. Interleukin-1β is the key player in the pathogenesis of OA, which induces the expression of various catabolic factors that contribute to cartilage degradation. Cynaroside (luteolin-7-O-glucoside or luteoloside) is a flavonoid that has various pharmacological properties, such as antitumor, anti-inflammatory, and antioxidant activities. In this study, we investigated the chondroprotective effects of cynaroside on IL-1β-stimulated chondrocytes and organ explants. The production of nitrite, PGE2, collagen type II, and aggrecan was measured by a Griess reagent and ELISAs, and the production of ROS was measured by H2DCF-DA fluorescence. The protein levels of iNOS, Cox-2, MMP-1, MMP-3, MMP-13, ADAMTS-4, MAPKs, and the NF-κB p65 subunit were measured by western blot. Proteoglycan analysis was performed by Alcian Blue staining (in vitro) and Safranin O staining (ex vivo). Cynaroside inhibited IL-1β-induced expression of catabolic factors (nitrite, iNOS, ROS, PGE2, Cox-2, MMP-1, MMP-3, MMP-13, and ADAMTS-4) and degradation of anabolic factors (collagen type II and aggrecan). Furthermore, cynaroside suppressed IL-1β-induced phosphorylation of MAPKs and translocation of the NF-κB p65 subunit into the nucleus. Collectively, these results suggest that cynaroside may be a potential candidate for the development of new therapeutic drugs for the alleviation of OA progression.


2002 ◽  
Vol 51 (2) ◽  
pp. 102-104 ◽  
Author(s):  
E. Lubberts ◽  
L. A. B. Joosten ◽  
F. A. J. van de Loo ◽  
P. Schwarzenberger ◽  
J. Kolls ◽  
...  

1992 ◽  
Vol 22 (1) ◽  
pp. 51-56 ◽  
Author(s):  
Tan Yan ◽  
Harald Burkhardt ◽  
Thomas Ritter ◽  
Barbara Bröker ◽  
Karl Heinz Mann ◽  
...  

1995 ◽  
Vol 40 (3) ◽  
pp. 181-185 ◽  
Author(s):  
H. Devlin ◽  
J. Hoyland ◽  
A.J. Freemont ◽  
P. Sloan

Sign in / Sign up

Export Citation Format

Share Document